Ivor Elrifi, Chief Executive Officer at Tiziana Life Sciences Ltd (TLSA), bought 321,423 shares at $0.97 ($319K) on 2026-08-04, disclosed to the SEC on 2026-08-06.
CEO Ivor Elrifi purchased $81,292.79 worth of shares at $0.97, signaling confidence in the company's clinical pipeline. This executive buying comes as the stock trades near a 52-week low following recent positive clinical data.
The stock has dropped 21.59% over the last 30 days and is currently 32.33% below its 52-week high of $1.46, trading at $0.988.
The stock is trading at a forward P/E of -5.69, indicating significant losses relative to current earnings expectations.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.97 | 83,807 | $81K | 25.5% |
| 2 | $1.00 | 237,616 | $238K | 74.5% |
| Total | $0.99 avg | 321,423 | $319K | 100% |